Compare TG Therapeutics Inc (TGTX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Under Armour Inc Class A — how do they compare? TG Therapeutics Inc trades at $55.11 (market cap $8.16B), while Under Armour Inc Class A trades at $4.92 (market cap $2.07B). The key difference: TG Therapeutics Inc is far larger — about 3.9× Under Armour Inc Class A's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Under Armour Inc Class A for 99 Days on average.
| TGTX | UAA | |
|---|---|---|
Market Cap | $8.16B | $2.07B |
Volume | 1,735,121 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $8.14 |
52-Week Low | $26.94 | $4.17 |
Typical Hold Time | 16 Days | 99 Days |
Enterprise Value | $8.37B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Under Armour (UAA) trades at $4.93, up 2.28% on the day, with a mixed technical outlook showing a bullish moving average signal but a neutral oscillator stance. The company reported a net loss of $201.27M in 2025, with revenue declining to $5.16B, though recent quarterly earnings have beaten expectations. Analyst consensus is a 'Hold' with a $5.79 price target, while news highlights the company's focus on product simplification and margin improvement amid softer demand.
The outlook remains challenging due to persistent revenue weakness and negative profitability, but cost discipline and international growth offer potential stabilization. Key risks include execution of the turnaround plan and competitive pressures. The stock presents a speculative opportunity for investors betting on a successful brand transformation, but requires careful risk assessment given the current financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
